SEARCH

SEARCH BY CITATION

References

  • 1
    Rimola A, Bory F, Planas R, Xaubet A, Bruguera M, Rodés J. Infecciones bacterianas en la cirrosis hepática. Gastroenterol Hepatol 1981; 4:453458.
  • 2
    Suárez C, Pajares JM. Epidemiología de las infecciones en la cirrosis hepática. Rev Clin Esp 1981; 160:299303.MEDLINE
  • 3
    Palazón JM, García A, Gómez A. Infecciones hospitalarias en pacientes con cirrosis hepática. Gastroenterol Hepatol 1984; 7:120122.
  • 4
    Andreu M, Barrufet P, Force L, Solà R, Verdaguer A, Panadés A, Aran R. Fiebre en el enfermo con cirrosis hepática: estudio prospectivo durante 6 meses. Med Clin (Barc) 1985; 84:433436.MEDLINE
  • 5
    Clemente G, Barajas JM, Serrano MI, Pérez de Ayala MV, Menchón P, Senent MC, Castellanos D, et al. Infecciones bacterianas en la cirrosis hepática. Gastroenterol Hepatol 1986; 9:291293.
  • 6
    Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:353358.MEDLINE
  • 7
    Rimola A. Infecciones bacterianas en la cirrosis hepática. MTA-Medicina Interna 1987; 5:161224.
  • 8
    Felisart J, Rimola A, Arroyo V, Pérez-Ayuso RM, Quintero E, Ginés P, Rodés J. Cefotaxime is more efective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5:457462.MEDLINE
  • 9
    Llovet JM, Planas R, Morillas R, Quer JC, Cabré E, Boix J, Humbert P, et al. Short-term prognosis of cirrhotic patients with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993; 88:388392.MEDLINE
  • 10
    Toledo C, Salmerón JM, Rimola A, Navasa M, Arroyo V, Llach J, Ginés A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17:251257.MEDLINE
  • 11
    Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 1997; 17:203217.MEDLINE
  • 12
    Runyon BA. Bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:271272.MEDLINE
  • 13
    Almdal TP, Skinhoj P. Spontaneous bacterial peritonitis in cirrhosis. Incidence, diagnosis and prognosis. Scand J Gastroenterol 1987; 22:295300.MEDLINE
  • 14
    Wyke RJ. Problems of bacterial infection in patients with liver disease. Gut 1987; 28:623641.MEDLINE
  • 15
    Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21:792796.MEDLINE
  • 16
    García-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993; 17:10811085.MEDLINE
  • 17
    Llovet JM, Bartolí R, Planas R, Cabré E, Jiménez M, Urban A, Ojanguren I, et al. Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut 1994; 35:16481652.MEDLINE
  • 18
    van der Waaij D, Manson WL, Arends JP, de Vries Hospers HG. Clinical use of selective decontamination: the concept. Intensive Care Med 1990; 16(Suppl 3):212S216S.
  • 19
    Rimola A, Bory F, Terés J, Pérez-Ayuso RM, Arroyo V, Rodés J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5:463467.MEDLINE
  • 20
    Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12:716724.MEDLINE
  • 21
    Soriano G, Guarner C, Teixidó M, Such J, Barrios J, Enríquez J, Vilardell F. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100:477481.MEDLINE
  • 22
    Soriano G, Guarner C, Tomás A, Villanueva C, Torras X, González D, Sáinz S, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103:12671272.MEDLINE
  • 23
    Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25:532536.MEDLINE
  • 24
    Grangé JD, Roulot D, Pelletier G, Pariente A, Denis J, Ink O, Blanc P, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29:430436.MEDLINE
  • 25
    Blaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994; 20:3438.MEDLINE
  • 26
    Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Lévy VG. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. Hepatology 1996; 24:802806.MEDLINE
  • 27
    Singh N, Gayowsky T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122:595598.MEDLINE
  • 28
    Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, Fratte S, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995; 22:11711174.MEDLINE
  • 29
    Tomás A, Soriano G, Guarner C, Portorreal R, Novella MT, Vilardell F. Hospital-acquired bacterial infections in patients with cirrhosis undergoing selective intestinal decontamination. J Hepatol 1993; 18:262263.MEDLINE
  • 30
    Muder RR, Brennen C, Goetz AM, Wagener MM, Rihs JD. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs Medical Center. Antimicrob Agents Chemother 1991; 35:256258.MEDLINE
  • 31
    Peña C, Albareda JM, Pallarés R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995; 39:520524.MEDLINE
  • 32
    Mirelis B, Miró E, Navarro F, Ogalla CA, Bonal J, Prats G. Increased resistance to quinolone in Catalonia, Spain. Diagn Microbiol Infect Dis 1993; 16:137139.MEDLINE
  • 33
    Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330:12401241.MEDLINE
  • 34
    Carratalà J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20:557560.MEDLINE
  • 35
    Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38:340344.MEDLINE
  • 36
    Castellote J, Xiol J, Rota Roca R, Fernández Esparrach G. Spontaneous bacterial peritonitis and empiema by Escherichia coli resistant to norfloxacin in a patient on selective intestinal decontamination with norfloxacin. J Hepatol 1994; 20:436.MEDLINE
  • 37
    Schubert ML, Sanyal AJ, Wong ES. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis? Gastroenterology 1991; 101:550552.MEDLINE
  • 38
    Daschner F. Emergence of resistance during selective decontamination of the digestive tract. Eur J Clin Microbiol Infect Dis 1992; 11:13.MEDLINE
  • 39
    Dejace P, Klastersky J. Emergence of resistance as a consequence of antimicrobial prophylaxis in immunocompromised patients. Scand J Infect Dis 1986; 49(Suppl):165S171S.
  • 40
    Ball P. Bacterial resistance to fluoroquinolones: lessons to be learned. Infection 1994; 22(Suppl 2):140S147S.
  • 41
    Sobel JD, Kaye D. Urinary tract infections. In: MandellGL, DouglasRG, BennettJE, eds. Principles and practice of infectious diseases. Ed. 3. New York: Churchill Livingstone, 1990;662690.
  • 42
    Young LS. Gram-negative sepsis. In: MandellGL, DouglasRG, BennettJE, eds. Principles and practice of infectious diseases. Ed. 3. New York: Churchill Livingstone, 1990;611635.
  • 43
    Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20:14951501.MEDLINE
  • 44
    Rimola A, Salmerón JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, Guarner C, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Results of a prospective, randomized, multicenter study. Hepatology 1995; 21:674679.MEDLINE
  • 45
    Navasa M, Planas R, Clemente G, Vargas V, Guarner C, Follo A, Llovet JM, et al. Oral ofloxacin vs intravenous cefotaxime in the treatment of non-complicated spontaneous bacterial peritonitis in cirrhosis. Results of a multicenter, randomized trial. Gastroenterology 1996; 111:10111017.MEDLINE
  • 46
    Grangé JD, Amiot X, Grangé V, Gutmann L, Biour M, Bodin F, Poupon R. Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology 1990; 11:360364.MEDLINE
  • 47
    Ricart E, Soriano G, Novella MT, Sàbat M, Kolle L, Ortiz J, Sola-Vera J, et al. Amoxicillin-clavulanic acid vs cefotaxime in the therapy of bacterial infections in cirrhotic patients [Abstract]. Hepatology 1997; 26:183A.
  • 48
    National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial disk susceptibility test. Approved standard M2-A4. National Committee for Clinical Laboratory Standards, 1990, Villanova, PA.
  • 49
    Holmes B, Brogden RN, Richards DM. Norfloxacin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1985; 30:482513.MEDLINE
  • 50
    Llovet JM, Rodríguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, Menacho M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. J Hepatol 1997; 26:8895.MEDLINE
  • 51
    Aparicio JR, Such J, Girona E, Gutiérrez A, de Vera F, Arroyo MA, Plazas J, et al. Increased detection of quinolone-resistant strains of Escherichia coli in rectal exudate from cirrhotic patients following selective intestinal decontamination with absence of clinical implications [Abstract]. Hepatology 1997; 26:289A.
  • 52
    Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in an experimental model of cirrhosis in rats. J Hepatol 1997; 26:13721378.MEDLINE
  • 53
    Sonstein SA, Burnham JC. Effect of low concentrations of quinolone antibiotics on bacterial virulence mechanisms. Diagn Microbiol Infect Dis 1993; 16:277289.MEDLINE
  • 54
    Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351:797799.MEDLINE
  • 55
    Pardo A, Viñado B, Santos J, Planas R, Cabré E, Moreno de la Vega V, Hombrados M, et al. Effect of cisapride on intestinal bacterial overgrowth due to gram-negative organisms in cirrhosis. A pilot, randomized, controlled study [Abstract]. J Hepatol 1997; 26(Suppl 1):101S.